Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

Saved in:
Bibliographic Details
Published inMetabolism, clinical and experimental Vol. 74; pp. 43 - 46
Main Authors Katsiki, Niki, Athyros, Vasilios G., Mikhailidis, Dimitri P., Mantzoros, Christos
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2017
Subjects
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Endocrinology & Metabolism
Humans
Hypercholesterolemia - drug therapy
Hypercholesterolemia - metabolism
Hypercholesterolemia - physiopathology
Proprotein Convertase 9 - antagonists & inhibitors
Proprotein Convertase 9 - metabolism
Randomized Controlled Trials as Topic
Risk
Serine Proteinase Inhibitors - adverse effects
Serine Proteinase Inhibitors - therapeutic use
Online AccessGet full text
ISSN0026-0495
1532-8600
1532-8600
DOI10.1016/j.metabol.2017.04.007

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0026-0495
1532-8600
1532-8600
DOI:10.1016/j.metabol.2017.04.007